Previous studies have acknowledged the crucial roles of T cells in the use of MSCs to treat GVHD, especially the associated inflammatory pathways, including TNF-α signaling, IL6 signaling, the IFN-γ response, and ROS in donor T cells (46–48). The gene discussed is TNF; the disease is graft versus host disease.